Samrat Pharmachem Intrinsic Value
Samrat Pharmachem (SAMRATPH) median intrinsic value is ₹444.00 from 3 valuation models (range ₹408–₹480), vs current price ₹222.00 — +100.0% upside (Trading Below Calculated Value), margin of safety 50.0%. For current market price and key ratios, visit SAMRATPH stock price BSE.
SAMRATPH Valuation Methods Summary — DCF, Graham Number & P/E
Samrat Pharmachem intrinsic value across 3 models vs current price ₹222.00 — upside/downside and value range per method. Also explore SAMRATPH price movement history to track price trends across different timeframes.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| Book Value Method | asset | ₹480.00 | ₹432.00 - ₹528.00 | +116.2% | Book Value/Share: ₹240.00, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹444.00 | ₹399.60 - ₹488.40 | +100.0% | Revenue/Share: ₹966.67, P/S: 2.0x |
| Simple DCF (5Y) | dcf | ₹407.50 | ₹326.00 - ₹489.00 | +83.6% | CF Growth: 15.0%, Discount: 15% |
SAMRATPH Intrinsic Value vs Market Price — All Valuation Models
Samrat Pharmachem fair value range ₹408–₹480 vs current market price ₹222.00 across 3 valuation models. Browse SAMRATPH cash flow statement for revenue, profit, balance sheet and cash flow data.
SAMRATPH Intrinsic Value Analysis — Undervalued or Overvalued?
Samrat Pharmachem median intrinsic value ₹444.00, current price ₹222.00 — Trading Below Calculated Value by 100.0%, margin of safety 50.0%.
What is the intrinsic value of SAMRATPH?
Based on our comprehensive analysis using 3 different valuation methods, the estimated intrinsic value of Samrat Pharmachem (SAMRATPH) is ₹444.00 (median value). With the current market price of ₹222.00, this represents a +100.0% variance from our estimated fair value.
The valuation range spans from ₹407.50 to ₹480.00, indicating ₹407.50 - ₹480.00.
Is SAMRATPH undervalued or overvalued?
Based on our multi-method analysis, Samrat Pharmachem (SAMRATPH) appears to be trading below calculated value by approximately 100.0%.
SAMRATPH Financial Health — Key Ratios vs Industry Benchmarks
Samrat Pharmachem financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Return on Equity | -2.8% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Asset Turnover Ratio | 2.38x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
SAMRATPH Cash Flow Quality — Operating & Free Cash Flow
Samrat Pharmachem operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹-10 Cr | ₹-10 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹9 Cr | ₹9 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹-9 Cr | ₹-11 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹18 Cr | ₹18 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹5 Cr | ₹4 Cr | Positive Free Cash Flow | 8/10 |